Xylobiose (Standard)

Xylobiose (1,4-β-D-Xylobiose; 1,4-D-Xylobiose) is an orally active Claudin 2/CLDN2 inhibitor and HSP27 inducer. Xylobiose works by regulating intestinal barrier function and glucose and lipid metabolism-related signaling pathways. Xylobiose inhibits CLDN2 expression to reduce intestinal permeability, induces HSP27 to enhance cell protection, and regulates the miR-122a/miR-33a axis to inhibit liver lipid synthesis and improve insulin resistance. Xylobiose can strengthen intestinal barrier integrity, reduce blood sugar and blood lipid levels, and reduce oxidative stress and inflammatory response. Xylobiose can be used in the study of type 2 diabetes and metabolic syndrome[1][2].

Product Specifications

CAS Number

[6860-47-5]

UNSPSC

12352005

Target

Claudin; HSP; TNF Receptor

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; Metabolic Enzyme/Protease

Field of Research

Metabolic Disease; Inflammation/Immunology

Smiles

O=C[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1[C@@H]([C@H]([C@H](O)CO1)O)O

Molecular Formula

C10H18O9

Molecular Weight

282.24

References & Citations

[1]Rini DM, et al. Xylobiose treatment strengthens intestinal barrier function by regulating claudin 2 and heat shock protein 27 expression in human Caco-2 cells. J Sci Food Agric. 2024 Mar 15;104 (4) :2518-2525.|[2]Lim E, et al. Xylobiose, an Alternative Sweetener, Ameliorates Diabetes-Related Metabolic Changes by Regulating Hepatic Lipogenesis and miR-122a/33a in db/db Mice. Nutrients. 2016 Dec 5;8 (12) :791